Welcome to our dedicated page for Alpha Tau Medical Ltd. Ordinary Shares news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical Ltd. Ordinary Shares stock.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) is at the forefront of oncology therapeutics, specializing in the research, development, and potential commercialization of the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology. Founded in 2016, this Israeli medical device company focuses on the innovative use of alpha radiation to treat solid tumors. The Alpha DaRT technology, initially developed at Tel Aviv University, has shown promising results in preclinical and early clinical trials for various types of cancer.
Core Business and Technology: The Alpha DaRT technology uses alpha-emitting radium-224 atoms to target and destroy cancer cells while sparing surrounding healthy tissue. This method involves inserting radioactive seeds into the tumor, which release short-lived alpha particles. These particles have high biological effectiveness and a short range, making them ideal for localized treatment of solid tumors.
The company's current clinical trials are focused on multiple cancer types, including pancreatic, liver, and recurrent cutaneous squamous cell carcinoma. These trials are being conducted in various locations, including the European Union and North America. Notably, Alpha Tau is advancing its pivotal U.S. multi-center trial, ReSTART, which aims to treat recurrent cutaneous squamous cell carcinoma, and is expected to produce significant data by 2024.
Recent Achievements: Alpha Tau has made substantial progress recently. In October 2023, the company announced a long-term lease agreement for a new manufacturing site in Hudson, New Hampshire, which will significantly boost its production capabilities. Additionally, the company reported promising interim results from its pancreatic cancer trial and treated its first patient with liver metastases in a feasibility and safety study in Montreal, Canada.
Financial Condition: As of September 30, 2023, the company reported cash, restricted cash, and deposits totaling $90.1 million, ensuring sufficient funds to support operations for at least two years. For the nine months ended September 30, 2023, R&D expenses were $18.9 million, reflecting increased investments in employee compensation, clinical trials, and pre-clinical studies.
Partnerships and Collaborations: Alpha Tau is also exploring strategic partnerships to expand its clinical and commercial footprint. Discussions with major biopharmaceutical companies are underway, particularly for the Japanese market, where the company has completed a successful clinical trial for head and neck cancers.
Forward-Looking Statements: The company remains committed to advancing its clinical programs and expanding its manufacturing capabilities. With a strong financial position and a pipeline of promising clinical trials, Alpha Tau is well-positioned to make significant strides in the fight against cancer.
For more information, visit Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) reassured investors regarding Silicon Valley Bank's recent closure, stating no financial ties existed that would impact operations. The company develops Alpha DaRT™, a therapy aimed at treating solid tumors with targeted alpha radiation, designed to minimize damage to surrounding healthy tissue. Founded in 2016, Alpha Tau focuses on furthering its technology's commercialization. The release includes forward-looking statements, cautioning that actual results may differ due to various factors including the need for regulatory approval and potential funding challenges.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) reported its 2022 financial results, achieving significant milestones in cancer treatment development. The company initiated its pivotal U.S. trial for recurrent cutaneous squamous cell carcinoma (ReSTART) and received Health Canada approval for a liver cancer feasibility trial. Financially, it recorded a net loss of $33.8 million, or $0.53 per share, compared to $27.3 million, or $0.67 per share in 2021. The cash balance stands at $105.4 million, securing operational runway for at least two years. Future focuses include expanding clinical trials and increasing production capacity.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) has announced the enrollment of its first two patients in the pivotal multicenter ReSTART trial, focusing on the treatment of recurrent cutaneous squamous cell carcinoma (cSCC) with its Alpha DaRT™ therapy. The trial aims to enroll up to 86 patients across the U.S., Canada, Europe, and Israel to evaluate efficacy and safety. Key endpoints include overall response rates and durability of response. CEO Uzi Sofer emphasized the milestone's significance for regulatory approval and recruitment efforts. The Alpha DaRT technology is designed for localized tumor treatment while preserving healthy tissue.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) has received an amended radioactive license from the Israeli Ministry of Environmental Protection, increasing its Thorium-228 limit from 30 milliCurie to 100 milliCurie. This change allows the Jerusalem facility to potentially produce up to 300,000 Alpha DaRT sources annually. Additionally, approvals for a pre-clinical radioactive lab have been obtained, enabling the company to conduct experiments with mice and rats. CEO Uzi Sofer emphasized the importance of expanding manufacturing capacity to meet growing clinical trial demands and to explore combination therapies in-house.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) has received authorization from Health Canada for a feasibility and safety study of its innovative alpha-radiation therapy, Alpha DaRT, in treating liver metastases. This study, set to be conducted at the McGill University Health Center, aims to recruit 10 patients undergoing a two-stage hepatectomy for colorectal cancer. The trial will assess the feasibility of delivering Alpha DaRT sources and monitor safety through adverse events. CEO Uzi Sofer emphasized this milestone expands Alpha DaRT's potential applications in treating hard-to-treat cancers, marking a significant step forward for the company.
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) announced its participation in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023, to be held at Citi HQ Conference Center in New York City.
The Alpha DaRT therapy, developed for treating solid tumors, utilizes radium-224 for targeted alpha-radiation intended to minimize damage to surrounding healthy tissue.
Founded in 2016, Alpha Tau focuses on advancing this innovative approach to cancer treatment, which was created by leading researchers from Tel Aviv University.
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) announced plans to present its alpha-radiation cancer therapy, Alpha DaRT™, at the upcoming Biotech Showcase in San Francisco, scheduled for January 9-12, 2023. CFO Raphi Levy will discuss the company’s technology, clinical progress, and upcoming trials, including a pivotal trial for recurrent cutaneous squamous cell carcinoma. Additionally, one-on-one institutional investor meetings will be available at both the Biotech Showcase and LifeSci Partners Corporate Access Event on January 10, 2023.
Alpha Tau Medical (Nasdaq: DRTS, DRTSW) reported its Q3 2022 financial results, showing a net loss of $2.6 million ($0.04 per share), significantly improved from a $4.8 million loss in Q3 2021. R&D expenses rose to $4.8 million, driven by increased personnel and study costs. The company remains focused on its upcoming U.S. pivotal study for recurrent cutaneous squamous cell carcinoma and has made significant strides in global commercialization. With a cash balance of $108.5 million, Alpha Tau is well-positioned to sustain operations for at least two years.
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) announced its participation in two investor conferences this November. The first event is the Jefferies London Healthcare Conference on November 16, 2022, at 4:25 PM GMT in London. The second is the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 1:30 PM EST in New York. The company focuses on the innovative alpha-radiation cancer therapy, Alpha DaRT, aimed at effectively targeting solid tumors while minimizing damage to surrounding healthy tissue.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announced significant advancements in its clinical research and trials. The Medicines and Healthcare products Regulatory Agency of the UK approved a trial for treating squamous cell carcinoma of the vulva, while Health Canada added a second site at Jewish General Hospital in Montreal for pancreatic cancer trials. Additionally, findings from a U.S. pilot study on the Alpha DaRT treatment will be presented at the upcoming ASTRO 2022 Annual Meeting. These developments illustrate Alpha Tau's commitment to expanding its innovative cancer therapies.
FAQ
What is the current stock price of Alpha Tau Medical Ltd. Ordinary Shares (DRTS)?
What is the market cap of Alpha Tau Medical Ltd. Ordinary Shares (DRTS)?
What is Alpha Tau Medical Ltd.?
What is Alpha DaRT?
Where is Alpha Tau conducting clinical trials?
What recent achievements has Alpha Tau announced?
What is the financial condition of Alpha Tau?
What partnerships is Alpha Tau exploring?
How does Alpha DaRT technology work?
What is the ReSTART trial?
What are the future plans for Alpha Tau's manufacturing capabilities?
Where can I find more information about Alpha Tau Medical Ltd.?
